Methods and kits that identify tumors responsive to Src inhibitors
US9279811B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 26, 2013 |
| Grant date | Mar 8, 2016 |
| Priority date | — |
| Expiry date | Nov 26, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/988
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed herein are methods of predicting whether or not a subject will benefit from treatment with a Src inhibitor on the basis of the expression of one or more of Von Hippel Lindau (VHL), Src, PTP1B, pFAK, HIF-1α, and/or CA-IX in a tumor sample from the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.